Background—
18
F-fluorocholine (
18
F-FCH) uptake is associated with cell proliferation and activity in tumor patients. We hypothesized that
18
F-FCH could similarly be a valuable imaging tool to identify vulnerable plaques and associated intraplaque inflammation and atheroma cell proliferation.
Methods and Results—
Ten consecutive stroke patients (90% men, median age 66.5 years, range, 59.4–69.7) with ipsilateral >70% carotid artery stenosis and who underwent carotid endarterectomy were included in the study. Before carotid endarterectomy, all patients underwent positron emission tomography to assess maximum
18
F-FCH uptake in ipsilateral symptomatic carotid plaques and contralateral asymptomatic carotid arteries, which was corrected for background activity, resulting in a maximum target-to-background ratio (TBRmax). Macrophage content was assessed in all carotid endarterectomy specimens as a percentage of CD68
+
-staining per whole plaque area (plaqueCD68
+
) and as a maximum CD68
+
percentage (maxCD68
+
) in the most inflamed section/plaque. Dynamic positron emission tomography imaging demonstrated that an interval of 10 minutes between
18
F-FCH injection and positron emission tomography acquisition is appropriate for carotid plaque imaging. TBRmax in ipsilateral symptomatic carotid plaques correlated significantly with plaqueCD68
+
(Spearman’s ρ=0.648,
P
=0.043) and maxCD68
+
(ρ=0.721,
P
=0.019) in the 10 corresponding carotid endarterectomy specimens. TBRmax was significantly higher (
P
=0.047) in ipsilateral symptomatic carotid plaques (median: 2.0; interquartile range [Q1–Q3], 1.5–2.5) compared with the contralateral asymptomatic carotid arteries (median: 1.4; Q1–Q3, 1.3–1.6). TBRmax was not significantly correlated to carotid artery stenosis (ρ=0.506,
P
=0.135).
Conclusions—
In vivo uptake of
18
F-FCH in human carotid atherosclerotic plaques correlated strongly with degree of macrophage infiltration and recent symptoms, thus
18
F-FCH positron emission tomography is a promising tool for the evaluation of vulnerable plaques.
Clinical Trial Registration—
URL:
http://www.clinicaltrials.gov
. Unique identifier: NCT01899014.